<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35370014</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0046</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>234</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence</Title>
          <ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021.</ArticleTitle>
        <Pagination>
          <StartPage>109398</StartPage>
          <MedlinePgn>109398</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugalcdep.2022.109398</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0376-8716(22)00135-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Prevalence of fentanyl-laced counterfeit prescription pills has been increasing in the US, possibly placing a wider population at risk for unintentional exposure. We aimed to determine whether there have been shifts in the number of fentanyl seizures and in the form of fentanyl seized in the US.</AbstractText>
          <AbstractText Label="METHODS">We examined quarterly national seizure data from High Intensity Drug Trafficking Areas to determine the number of drug seizures in the US containing fentanyl from January 2018 through December 2021. Generalized additive models were used to estimate trends in the number and weight of pill and powder seizures containing fentanyl.</AbstractText>
          <AbstractText Label="RESULTS">There was an increase both in the number of fentanyl-containing powder seizures (from 424 in 2018 Quarter 1 [Q1] to 1539 in 2021 Quarter 4 [Q4], β = 0.94, p &lt; 0.001) and in the number of pill seizures (from 68 to 635, β = 0.96, p &lt; 0.01). The proportion of pills to total seizures more than doubled from 13.8% in 2018 Q1 to 29.2% in 2021 Q4 (β = 0.92, p &lt; 0.001). Weight of powder fentanyl seizures increased from 298.2 kg in 2018 Q1 to 2416.0 kg in 2021 Q4 (β = 1.12, p = 0.01); the number of pills seized increased from 42,202 in 2018 Q1 to 2,089,186 in 2021 Q4 (β = 0.90, p &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Seizures of drugs containing fentanyl have been increasing in the US. Given that over a quarter of fentanyl seizures are now in pill form, people who obtain counterfeit pills such as those disguised as oxycodone or alprazolam are at risk for unintentional exposure to fentanyl.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Palamar</LastName>
            <ForeName>Joseph J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>New York University Grossman School of Medicine, Department of Population Health, New York, NY, USA. Electronic address: joseph.palamar@nyulangone.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ciccarone</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>University of California, San Francisco, Department of Family and Community Medicine, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rutherford</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keyes</LastName>
            <ForeName>Katherine M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carr</LastName>
            <ForeName>Thomas H</ForeName>
            <Initials>TH</Initials>
            <AffiliationInfo>
              <Affiliation>College of Public Affairs, Center for Drug Policy and Prevention, University of Baltimore, United States; Office of National Drug Control Policy, Washington, Baltimore High Intensity Drug Trafficking Areas Program, United States, Center for Drug Policy and Prevention, University of Baltimore, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cottler</LastName>
            <ForeName>Linda B</ForeName>
            <Initials>LB</Initials>
            <AffiliationInfo>
              <Affiliation>NDEWS, University of Florida, United States; University of Florida, Department of Epidemiology, College of Public Health and Health Professions, College of Medicine, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DA044207</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DA054190</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 DA051126</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Alcohol Depend</MedlineTA>
        <NlmUniqueID>7513587</NlmUniqueID>
        <ISSNLinking>0376-8716</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013287">Illicit Drugs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011208">Powders</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>CD35PMG570</RegistryNumber>
          <NameOfSubstance UI="D010098">Oxycodone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>UF599785JZ</RegistryNumber>
          <NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005283" MajorTopicYN="N">Fentanyl</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013287" MajorTopicYN="Y">Illicit Drugs</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010098" MajorTopicYN="N">Oxycodone</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Counterfeit pills</Keyword>
        <Keyword MajorTopicYN="Y">Drug seizures</Keyword>
        <Keyword MajorTopicYN="Y">Fentanyl</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35370014</ArticleId>
        <ArticleId IdType="mid">NIHMS1787797</ArticleId>
        <ArticleId IdType="pmc">PMC9027012</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugalcdep.2022.109398</ArticleId>
        <ArticleId IdType="pii">S0376-8716(22)00135-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahmad FB, Rossen LM, Sutton P, 2021, Provisional drug overdose death counts. National Center for Health Statistics. Available at: ⟨https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#citation⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Aldy K, Mustaquim D, Campleman S, Meyn A, Abston S, Krotulski A, Logan B, Gladden MR, Hughes A, Amaducci A, Shulman J, Schwarz E, Wax P, Brent J, Manini A, 2021. Notes from the field: Illicit benzodiazepines detected in patients evaluated in emergency departments for suspected opioid overdose - four states, October 6, 2020-March 9, 2021. MMWR Morb. Mortal. Wkly Rep
70 (34), 1177–1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8389390</ArticleId>
            <ArticleId IdType="pubmed">34437520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arens AM, van Wijk XM, Vo KT, Lynch KL, Wu AH, Smollin CG, 2016. Adverse effects from counterfeit alprazolam tablets. JAMA Intern Med
176 (10), 1554–1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27532131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR, 2017. Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in Central California: A case report. Ann. Emerg. Med
69 (1), 87–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27473610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunt TM, Nagy C, Bucheli A, Martins D, Ugarte M, Beduwe C, Ventura Vilamala M, 2016. Drug Testing in Europe: Monitoring Results of the Trans European Drug Information (TEDI) Project. Drug Test. Anal
9 (2), 188–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26888408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciccarone D, 2019. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int. J. Drug Policy
71, 183–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6675668</ArticleId>
            <ArticleId IdType="pubmed">30718120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciccarone D, Ondocsin J, Mars SG, 2017. Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and -substituted ‘heroin’. Int J. Drug Policy
46, 146–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5577861</ArticleId>
            <ArticleId IdType="pubmed">28735775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottler LB, Goldberger BA, Nixon SJ, Striley CW, Barenholtz E, Fitzgerald ND, Taylor SM, Palamar JJ, 2020. Introducing NIDA’s New National Drug Early Warning System. Drug Alcohol Depend. 217, 108286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7489265</ArticleId>
            <ArticleId IdType="pubmed">32979739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta N, Figgatt MC, 2021. Drug checking for novel insights into the unregulated drug supply. Am. J. Epidemiol
191 (2), 248–252.</Citation>
        </Reference>
        <Reference>
          <Citation>DiSalvo P, Cooper G, Tsao J, Romeo M, Laskowski LK, Chesney G, Su MK, 2020. Fentanyl-contaminated cocaine outbreak with laboratory confirmation in New York City in 2019. Am. J. Emerg. Med
40, 103–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33360606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Monitoring Centre for Drugs and Drug Addiction, 2021, European Drug Report 2021: Trends and Developments. Publications Office of the European Union, Luxembourg. Available at: ⟨https://www.emcdda.europa.eu/publications/edr/trends-developments/2021_en⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Gladden RM, Martinez P, Seth P, 2016. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. MMWR Morb. Mortal. Wkly Rep
65 (33), 837–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27560775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedegaard H, Miniño AM, Warner M, 2020. Drug overdose deaths in the United States, 1999-2019. NCHS Data Brief. 394, 1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hempstead K, Phillips J, 2019. divergence in recent trends in deaths from intentional and unintentional poisoning. Health Aff. 38 (1), 29–35.</Citation>
        </Reference>
        <Reference>
          <Citation>High Intensity Drug Trafficking Area, 2019, Annual report 2019. Available at: ⟨https://www.hidta.org/wp-content/uploads/2020/04/AnnualReport_2019_final.pdf⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Jones JD, Mogali S, Comer SD, 2012. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 125 (1–2), 8–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3454351</ArticleId>
            <ArticleId IdType="pubmed">22857878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joynt PY, Wang GS, 2021. Fentanyl contaminated “M30” pill overdoses in pediatric patients. Am. J. Emerg. Med
50, 811 e3–811.e4.</Citation>
        </Reference>
        <Reference>
          <Citation>Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE, 2019. Fentanyl and drug overdose: Perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst. Use Misuse
54 (6), 998–1006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6476669</ArticleId>
            <ArticleId IdType="pubmed">30767590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCabe SE, Teter CJ, Boyd CJ, Wilens TE, Schepis TS, 2018. Sources of prescription medication misuse among young adults in the United States: The role of educational status. J. Clin. Psychiatry
79 (2), 17m11958.</Citation>
        </Reference>
        <Reference>
          <Citation>Measham FC, 2019. Drug safety testing, disposals and dealing in an English field: Exploring the operational and behavioural outcomes of the UK’s first onsite ‘drug checking’ service. Int J. Drug Policy
67, 102–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30541674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute on Drug Abuse, 2021, Benzodiazepines and Opioids. Available at: ⟨https://nida.nih.gov/drug-topics/opioids/benzodiazepines-opioids⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Olives TD, Arens AM, Kloss JS, Apple FS, Cole JB, 2017. The new face of heroin. Am. J. Emerg. Med
35 (12), 1978–1979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28716592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palamar JJ, Acosta P, Sutherland R, Shedlin MG, Barratt MJ, 2019. Adulterants and altruism: A qualitative investigation of “drug checkers” in North America. Int. J. Drug Policy
74, 160–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6893085</ArticleId>
            <ArticleId IdType="pubmed">31610451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palamar JJ, Fitzgerald ND, Cottler LB, 2021b. Shifting awareness among electronic dance music party attendees that drugs may contain fentanyl or other adulterants. Int J. Drug Policy
97, 103353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8585682</ArticleId>
            <ArticleId IdType="pubmed">34242960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palamar JJ, Le A, Carr TH, Cottler LB, 2021a. Shifts in drug seizures in the United States during the COVID-19 pandemic. Drug Alcohol Depend. 221, 108580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8026667</ArticleId>
            <ArticleId IdType="pubmed">33674175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palamar JJ, Salomone A, Barratt MJ, 2020. Drug checking to detect fentanyl and new psychoactive substances. Curr. Opin. Psychiatry
33 (4), 301–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7255931</ArticleId>
            <ArticleId IdType="pubmed">32187173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardo B, 2020, Considering the harms drug supply indicators. RAND Working Paper. RAND Drug Policy Research Center. Available at: ⟨https://www.rand.org/pubs/working_papers/WR1339.html⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Park JN, Frankel S, Morris M, Dieni O, Fahey-Morrison L, Luta M, Hunt D, Long J, Sherman SG, 2021a. Evaluation of fentanyl test strip distribution in two Mid-Atlantic syringe services programs. Int J. Drug Policy
94, 103196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33713964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JN, Rashidi E, Foti K, Zoorob M, Sherman S, Alexander GC, 2021b. Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011-2016. Drug Alcohol Depend. 218, 108416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7751390</ArticleId>
            <ArticleId IdType="pubmed">33278761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE, 2018. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Int. J. Drug Policy
63, 122–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30292493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenblum D, Unick J, Ciccarone D, 2020. The rapidly changing US illicit drug market and the potential for an improved early warning system: Evidence from Ohio drug crime labs. Drug Alcohol Depend. 208, 107779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7096152</ArticleId>
            <ArticleId IdType="pubmed">31931266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slavova S, Costich JF, Bunn TL, Luu H, Singleton M, Hargrove SL, Triplett JS, Quesinberry D, Ralston W, Ingram V, 2017. Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance. Int J. Drug Policy
46, 120–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28735777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Substance Abuse and Mental Health Services Administration, 2021, Federal grantees may now use funds to purchase fentanyl test strips. Available at: ⟨https://www.samhsa.gov/newsroom/press-announcements/202104070200⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, Adams AJ, Owen KP, Ford JB, Black HB, Albertson TE, 2017. Fatal fentanyl: One pill can kill. Acad. Emerg. Med
24 (1), 106–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27322591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki J, El-Haddad S, 2017. A review: Fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 171, 107–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28068563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Drug Enforcement Administration, 2017, Deadly Contaminated Cocaine Widespread in Florida, DEA-MIA-BUL-039–18. Available at: ⟨https://www.dea.gov/sites/default/ffles/2018–07/BUL-039–18.pdf⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>US Drug Enforcement Administration, 2021c, National Forensic Laboratory Information System: NFLIS-Drug 2020 Annual Report. Springfield, VA. Available at: ⟨https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>US Drug Enforcement Administration, 2021a, 2020 National Drug Threat Assessment, DEA DCT-DIR-008–21. Available at: ⟨https://www.dea.gov/documents/2021/03/02/2020-national-drug-threat-assessment⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>US Drug Enforcement Administration, 2021b, DEA seizes historic amounts of deadly fentanyl-laced fake pills in public safety surge to protect U.S. communities. Available at: ⟨https://www.dea.gov/press-releases/2021/09/30/dea-seizes-historic-amounts-deadly-fentanyl-laced-fake-pills-public⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>US Drug Enforcement Administration, 2022, Facts about Fentanyl. Available at: ⟨https://www.dea.gov/resources/facts-about-fentanyl⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>US Sentencing Commission, 2017, Statement of Srihari R. Telia, Ph.D, Unit Chief, Drug and Chemical Control Unit Drug and Chemical Evaluation Section, Diversion Control Division Drug Enforcement Administration before the United States Sentencing Commission for a public hearing on fentanyl and synthetic cannabinoids. Available at: ⟨https://www.ussc.gov/sites/default/files/pdf/amendment-process/public-hearings-and-meetings/20171205/Tella.pdf⟩ (accessed on 2 March 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Zibbell JE, Aldridge AP, Cauchon D, DeFiore-Hyrmer J, Conway KP, 2019. Association of law enforcement seizures of heroin, fentanyl, and carfentanil with opioid overdose deaths in Ohio, 2014-2017. JAMA Netw. Open
2 (11), e1914666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6902770</ArticleId>
            <ArticleId IdType="pubmed">31702795</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
